Introduction

When someone bleeds easily, the cause is usually one of three things: a problem with the platelets, a problem with clotting factors, or a problem with the blood vessel wall itself. Vascular bleeding disorders make up the third group. They are a diverse set of conditions where capillaries and small vessels leak too easily, producing bruises and surface bleeds that can look dramatic but are often misunderstood.

Physiology of Normal Hemostasis

Hemostasis has three layers working together. The vessel wall constricts and exposes collagen, the platelets form a plug, and the clotting factors weave a fibrin mesh that locks the plug in place. Fibrinolysis then dissolves the clot when healing is done.

Vascular bleeding disorders affect the first layer. Platelets and clotting factors are usually working fine but they cannot do their job properly because the wall they are trying to repair is too fragile, too inflamed, or abnormally formed.

Causes of Abnormal Bleeding

It helps to compare vascular bleeding disorders with the other two categories so the diagnostic picture is clear.

Platelet problems can be quantitative (low platelet count, called thrombocytopenia for example, immune thrombocytopenia) or qualitative (normal count but poor function, as in Glanzmann thrombasthenia or aspirin use).

Coagulation factor problems are usually inherited, like hemophilia A, hemophilia B, and von Willebrand disease. Acquired causes include liver disease, vitamin K deficiency, and anticoagulant medications such as warfarin.

Vessel wall problems are the focus of this article. Inherited forms weaken or malform the vessel itself; acquired forms inflame the vessel or rob it of its collagen and supporting tissue.

WHO Bleeding Grades

The World Health Organization bleeding scale gives clinicians a shared language for describing bleeding severity. The original scale runs 0 to 4. A grade 5 (fatal bleeding) is sometimes added in clinical literature but is not part of the original WHO grading.

While the WHO scale is widely used to grade acute bleeding severity, the clinical gold standard for evaluating suspected inherited bleeding disorders is the ISTH-BAT (International Society on Thrombosis and Haemostasis Bleeding Assessment Tool). The ISTH-BAT provides a standardized, quantifiable score based on the severity and frequency of a patient's bleeding history across categories like epistaxis, cutaneous bleeding, and menorrhagia. An elevated ISTH-BAT score helps clinicians determine which patients require specialized hemostasis laboratory testing [9].

Petechiae, Purpura, and Ecchymoses

These three terms describe bleeding into the skin, separated by size.

• Petechiae are pinpoint red or purple dots under 3 mm. Think of a speck of pepper. They do not blanch under pressure and often signal platelet dysfunction or fragile vessels.
• Purpura are larger spots, 4 to 10 mm — about the size of a lentil. They also do not blanch.
• Ecchymoses are bruises larger than 1 cm. They evolve through red, purple, blue, green, and yellow as the body breaks down the trapped blood.

How Vascular Bleeding Differs from Coagulopathies

The pattern of bleeding is the first big clue at the bedside. Vascular and platelet disorders bleed outward and superficially. Clotting factor disorders bleed inward and deep.

A useful rule for vascular bleeding disorders: platelet count is normal, PT is normal, aPTT is normal. If a patient has clear bleeding and these three are all unremarkable, the vessel wall is a strong suspect. Modern platelet function assessment now uses the PFA-100 or PFA-200 and platelet aggregometry, which have largely replaced the older bedside bleeding time.

Inherited Vascular Bleeding Disorders

Hereditary Hemorrhagic Telangiectasia (HHT)

HHT, also called Osler-Weber-Rendu syndrome, is an autosomal dominant disorder affecting roughly 1 in 5,000 people [1]. Mutations in genes that guide blood vessel formation (most commonly ENG and ACVRL1) lead to abnormal vessel architecture, with telangiectases on the skin and mucous membranes and larger arteriovenous malformations (AVMs) in the lungs, liver, and brain.

Clinical features. Recurrent nosebleeds usually begin in childhood. Small red telangiectases appear on the lips, tongue, fingers, and nasal mucosa. Pulmonary AVMs can cause stroke or brain abscess by allowing emboli to bypass the lung's filtering capillaries. Gastrointestinal telangiectases bleed silently and cause iron-deficiency anemia.

Diagnosis: the Curaçao criteria. HHT is diagnosed using four criteria [1]:

1. Recurrent and spontaneous epistaxis
2. Multiple telangiectases at characteristic sites
3. Visceral involvement (pulmonary, hepatic, cerebral, or GI AVMs)
4. A first-degree relative with HHT

Three or more criteria mean definite HHT; two are suspected HHT. Genetic testing confirms the diagnosis when needed.

Modern management. The Second International HHT Guidelines (2020) set out a stepped approach [1]:

• Topical nasal moisturizers are first-line for epistaxis.
• Oral tranexamic acid is added if moisturizers fail.
• Ablative therapies (laser, radiofrequency, sclerotherapy) target persistent nasal telangiectases.
• Systemic anti-VEGF therapy with bevacizumab is now established for refractory bleeding and chronic anemia. A 2025 meta-analysis of 225 patients showed a mean drop in epistaxis severity score of −3.33 and a mean hemoglobin rise of 2.38 g/dL after systemic bevacizumab [6].
• Iron repletion (oral or intravenous) is essential, since chronic blood loss is the rule, not the exception.
• Emerging oral agents such as pazopanib and VAD044 (which received FDA Fast Track designation in late 2024) are being studied for patients who cannot tolerate bevacizumab infusions [5].

Older drugs like thalidomide and lenalidomide remain options for refractory GI bleeding but are less commonly used today.

Connective Tissue Disorders

Several inherited disorders weaken the collagen and elastin that hold vessel walls together.

Ehlers-Danlos syndrome (EDS) is a group of disorders affecting collagen [7]. Patients often have hyperextensible joints and stretchy, fragile skin. The vascular type of EDS (vEDS) is the most dangerous and is caused by mutations in the COL3A1 gene, which encodes type III procollagen. In vEDS, arteries and hollow organs can rupture without warning. Bruising, mucosal bleeding, and poor wound healing are typical. Identifying the COL3A1 mutation via genetic testing is mandatory, as it dictates strict avoidance of invasive arterial procedures (such as standard angiography), which can cause fatal vessel rupture [10].

Pseudoxanthoma elasticum (PXE) affects elastic fibers in the skin, eyes, and vessels. The most common bleeding manifestation is gastrointestinal hemorrhage. Patients can also develop premature cardiovascular disease.

Diagnosis rests on clinical criteria, family history, and genetic testing. Management focuses on injury prevention, vessel surveillance, and managing complications as they arise.

Vascular Tumors and Kasabach-Merritt Phenomenon 

While most vascular anomalies present as simple structural defects, specific pediatric vascular tumors (namely Kaposiform hemangioendothelioma and tufted angioma) can trigger a life-threatening hematologic emergency known as Kasabach-Merritt Phenomenon (KMP). In KMP, the abnormal tumor vasculature traps and destroys platelets, leading to profound thrombocytopenia and a severe consumptive coagulopathy [11]. This demonstrates how a localized structural vessel wall defect can secondarily disrupt systemic platelets and clotting factors, requiring aggressive medical management to shrink the tumor and halt the coagulopathy.

Acquired Vascular Defects

Most vascular bleeding disorders seen in everyday practice are acquired, not inherited.

Simple Easy Bruising

Many otherwise healthy people bruise more readily than average. The cause is often unknown. Aging, sun damage, aspirin, and anticoagulants all play a role. Bruising without other bleeding symptoms, normal lab tests, and no medication trigger usually needs no specific treatment.

Senile Purpura

In older adults, the skin and the supporting tissue around small vessels thin out. Even gentle bumps cause flat purple patches on the forearms and backs of the hands. The lesions are unsightly but harmless. No treatment is needed unless bleeding is heavy.

AL Amyloidosis 

In AL amyloidosis, a plasma cell dyscrasia leads to the systemic deposition of insoluble amyloid fibrils within the walls of capillaries and small blood vessels, making them extremely fragile. This classically presents as "pinch purpura" (bruising after minimal skin traction) or periorbital ecchymoses ("raccoon eyes") following a cough, sneeze, or minor trauma [12]. It is a critical diagnostic clue for underlying hematologic malignancies in older adults presenting with unexplained superficial bleeding.

Dysproteinemias and Hyperviscosity 

Conditions characterized by abnormal circulating proteins, such as Waldenström's macroglobulinemia or Multiple Myeloma, can cause vascular bleeding. Excess immunoglobulins can directly damage the vascular endothelium through hyperviscosity or coat platelets to induce secondary dysfunction, resulting in spontaneous mucosal bleeding, epistaxis, and purpura [13].

Purpura Associated with Infections

Some infections damage vessels directly or trigger immune-mediated injury. Meningococcemia is the dangerous example where purpura can spread rapidly within hours and signals sepsis. Viral illnesses such as infectious mononucleosis cause milder purpura. Diagnosis combines clinical findings, blood cultures, and sometimes skin biopsy. Treatment targets the infection.

IgA Vasculities (formerly Henoch-Schönlein Purpura (HSP))

The disease many textbooks still call Henoch-Schönlein purpura (HSP) was officially renamed IgA vasculitis (IgAV) by the 2012 Chapel Hill Consensus Conference [3,4]. It is the most common vasculitis in children, with an annual incidence of about 15 per 100,000 in pediatric populations and 1.3 per 100,000 in adults [2].

Cause. IgA vasculitis follows an immune trigger, most often an upper respiratory infection, but also bacterial infections, vaccines, drugs, or, more recently, COVID-19. Abnormally glycosylated IgA1 forms immune complexes that deposit in small vessels [2].

Clinical tetrad:

1. Palpable purpura, classically on the buttocks and lower legs
2. Arthralgia or arthritis
3. Abdominal pain (sometimes with GI bleeding)
4. IgA vasculitis nephritis — blood and protein in the urine

Diagnosis is clinical, supported by urinalysis to check for kidney involvement. Skin biopsy can show IgA deposits if the diagnosis is uncertain.

Management is mostly supportive: rest, hydration, and pain relief. Corticosteroids are used for severe abdominal pain or kidney involvement. The crucial follow-up is urinalysis for at least six months, because IgAV nephritis can appear weeks after the rash has cleared [2]. Most children recover fully, but adults have a more severe course, with 10–30% progressing to end-stage kidney disease [2,8].

Scurvy (Vitamin C Deficiency)

Vitamin C is needed to make collagen, the scaffolding of blood vessel walls. Severe deficiency causes easy bruising, bleeding gums, fatigue, and poor wound healing. Although scurvy is rare in well-nourished populations, it still appears in people with restricted diets, alcohol misuse, or eating disorders. Diagnosis combines clinical features with low serum vitamin C levels. Vitamin C replacement reverses symptoms within days to weeks.

Steroid Purpura

Long-term high-dose corticosteroids and the endogenous excess of Cushing's syndrome reduce the dermal collagen and perivascular connective tissue that normally support small vessels. Easy bruising and purpura appear, particularly on sun-exposed forearms and hands. Diagnosis is usually clinical. Management means minimizing steroid dose where possible and protecting the skin.

Investigations at a Glance

Conclusion

Vascular bleeding disorders are a small but important slice of bleeding pathology. They live in the gap between platelet disorders and coagulopathies where the lab tests look normal, yet the patient bleeds. Inherited forms (HHT, EDS, PXE) need lifelong surveillance and increasingly benefit from targeted therapies like bevacizumab. Acquired forms (IgA vasculitis, scurvy, steroid purpura, senile purpura, infectious purpura) usually trace back to a clear cause and respond to treating that cause.

Frequently Asked Questions (FAQs)

What are vascular bleeding disorders?

Vascular bleeding disorders are conditions where the blood vessel wall itself is too fragile or inflamed, causing easy bruising and small-vessel bleeding. Platelet count and standard clotting tests (PT and aPTT) are usually normal, which is what sets this group apart from platelet disorders or hemophilia.

Is Henoch-Schönlein purpura the same as IgA vasculitis?

Yes. Since the 2012 Chapel Hill Consensus, the disease has been renamed IgA vasculitis (IgAV). The older name is still used in clinical practice, but textbooks and exams increasingly use IgAV. The disease itself has not changed: it is a small-vessel vasculitis driven by IgA immune deposits, mainly affecting children after a respiratory infection.

Can vitamin deficiency cause vascular bleeding?

Yes. The classic example is scurvy, caused by severe vitamin C deficiency. Without enough vitamin C, the body cannot make collagen properly, and blood vessel walls become fragile. Easy bruising, bleeding gums, and poor wound healing improve quickly once vitamin C is replaced.

Glossary of Related Medical Terms

• Vascular bleeding disorders — A group of conditions in which the blood vessel wall, rather than platelets or clotting factors, is the main reason for bleeding.
• Hemostasis — The body's process of stopping bleeding after a blood vessel is injured.
• Petechiae — Tiny pinpoint red or purple spots in the skin, usually under 3 mm, caused by leakage from small vessels.
• Purpura — Red or purple skin patches, larger than petechiae (4–10 mm), that do not turn pale when pressed.
• Ecchymosis — A bruise larger than 1 cm, caused by blood leaking into the skin from broken vessels.
• Telangiectasia — A small, dilated blood vessel visible on the skin or mucous membrane.
• Vasculitis — Inflammation of blood vessels, which can damage the vessel wall and cause bleeding or organ injury.
• IgA vasculitis (IgAV) — The current name for Henoch-Schönlein purpura, a small-vessel vasculitis driven by IgA immune deposits.
• Hereditary hemorrhagic telangiectasia (HHT) — An inherited disorder causing abnormal vessel formation, leading to nosebleeds and bleeding in internal organs.
• Curaçao criteria — The four clinical criteria used to diagnose HHT: recurrent epistaxis, telangiectases, visceral lesions, and family history.
• Bevacizumab — A monoclonal antibody that blocks vascular endothelial growth factor (VEGF), now used to control bleeding in HHT.
• Tranexamic acid (TXA) — A medication that reduces bleeding by slowing clot breakdown.
• PFA-100/200 — A modern bench-top test of platelet function that has largely replaced the older bleeding time test.
• Collagen — A structural protein that gives strength to blood vessel walls; vitamin C is needed to make it.
• Hemarthrosis — Bleeding into a joint, typical of coagulation factor deficiencies rather than vascular disorders.

Disclaimer: This article is intended for educational and informational purposes only. It is not intended to be a substitute for informed professional medical advice, diagnosis, or treatment. While the information presented here is derived from credible medical sources and is believed to be accurate and up-to-date, it is not guaranteed to be complete or error-free. See additional information.

References

1. Faughnan, M. E., Mager, J. J., Hetts, S. W., Palda, V. A., Lang-Robertson, K., Buscarini, E., Deslandres, E., Kasthuri, R. S., Lausman, A., Poetker, D., Ratjen, F., Chesnutt, M. S., Clancy, M., Whitehead, K. J., Al-Samkari, H., Chakinala, M., Conrad, M., Cortes, D., Crocione, C., Darling, J., … Zarrabeitia, R. (2020). Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Annals of internal medicine, 173(12), 989–1001. https://doi.org/10.7326/M20-1443
2. Pillebout, E., & Sunderkötter, C. (2021). IgA vasculitis. Seminars in immunopathology, 43(5), 729–738. https://doi.org/10.1007/s00281-021-00874-9
3. Sunderkötter, C. H., Zelger, B., Chen, K. R., Requena, L., Piette, W., Carlson, J. A., Dutz, J., Lamprecht, P., Mahr, A., Aberer, E., Werth, V. P., Wetter, D. A., Kawana, S., Luqmani, R., Frances, C., Jorizzo, J., Watts, J. R., Metze, D., Caproni, M., Alpsoy, E., … Jennette, J. C. (2018). Nomenclature of Cutaneous Vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis & rheumatology (Hoboken, N.J.), 70(2), 171–184. https://doi.org/10.1002/art.40375
4. Parums D. V. (2024). A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future. Medical science monitor : international medical journal of experimental and clinical research, 30, e943912. https://doi.org/10.12659/MSM.943912
5. Eswaran, H., & Kasthuri, R. S. (2024). Potential and emerging therapeutics for HHT. Hematology. American Society of Hematology. Education Program, 2024(1), 724–727. https://doi.org/10.1182/hematology.2024000675
6. Li, W., Bai, J., Symons, A., Banting, J., & Rimmer, J. (2025). The Effect of Systemic Bevacizumab on Epistaxis-Related Outcomes in Hereditary Hemorrhagic Telangiectasia: A Systematic Review and Meta-Analysis. International forum of allergy & rhinology, 15(8), 803–817. https://doi.org/10.1002/alr.23566
7. Malfait, F., Castori, M., Francomano, C. A., Giunta, C., Kosho, T., & Byers, P. H. (2020). The Ehlers-Danlos syndromes. Nature reviews. Disease primers, 6(1), 64. https://doi.org/10.1038/s41572-020-0194-9
8. Audemard-Verger, A., Pillebout, E., Baldolli, A., Gouellec, N. L., Augusto, J. F., Jourde-Chiche, N., Raffray, L., Thervet, E., Deroux, A., Goutte, J., Hummel, A., Lioger, B., Sanges, S., Cacoub, P., Amoura, Z., Moulis, G., Maurier, F., Lavigne, C., Urbanski, G., Chanal, J., … Terrier, B. (2021). Impact of aging on phenotype and prognosis in IgA vasculitis. Rheumatology (Oxford, England), 60(9), 4245–4251. https://doi.org/10.1093/rheumatology/keaa921
9. Rodeghiero, F., Tosetto, A., Abshire, T., Arnold, D. M., Coller, B., James, P., Neunert, C., Lillicrap, D., & ISTH/SSC joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group (2010). ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. Journal of thrombosis and haemostasis : JTH, 8(9), 2063–2065. https://doi.org/10.1111/j.1538-7836.2010.03975.x
10. Malfait, F., Francomano, C., Byers, P., Belmont, J., Berglund, B., Black, J., Bloom, L., Bowen, J. M., Brady, A. F., Burrows, N. P., Castori, M., Cohen, H., Colombi, M., Demirdas, S., De Backer, J., De Paepe, A., Fournel-Gigleux, S., Frank, M., Ghali, N., Giunta, C., … Tinkle, B. (2017). The 2017 international classification of the Ehlers-Danlos syndromes. American journal of medical genetics. Part C, Seminars in medical genetics, 175(1), 8–26. https://doi.org/10.1002/ajmg.c.31552
11. Wassef, M., Blei, F., Adams, D., Alomari, A., Baselga, E., Berenstein, A., Burrows, P., Frieden, I. J., Garzon, M. C., Lopez-Gutierrez, J. C., Lord, D. J., Mitchel, S., Powell, J., Prendiville, J., Vikkula, M., & ISSVA Board and Scientific Committee (2015). Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular Anomalies. Pediatrics, 136(1), e203–e214. https://doi.org/10.1542/peds.2014-3673
12. Wechalekar, A. D., Gillmore, J. D., & Hawkins, P. N. (2016). Systemic amyloidosis. Lancet (London, England), 387(10038), 2641–2654. https://doi.org/10.1016/S0140-6736(15)01274-X
13. Gertz M. A. (2019). Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. American journal of hematology, 94(2), 266–276. https://doi.org/10.1002/ajh.25292